Oral levosimendan in amyotrophic lateral sclerosis : a phase II multicentre, randomised, double-blind, placebo-controlled trial

Al-Chalabi, A., Shaw, P. orcid.org/0000-0002-8925-2567, Leigh, P.N. et al. (6 more authors) (2019) Oral levosimendan in amyotrophic lateral sclerosis : a phase II multicentre, randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery & Psychiatry. ISSN 0022-3050

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 The Authors. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Keywords: SVC; amyotrophic lateral sclerosis; levosimendan; respiratory function
Dates:
  • Accepted: 10 June 2019
  • Published (online): 17 July 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 30 Jul 2019 08:47
Last Modified: 30 Jul 2019 08:47
Status: Published online
Publisher: BMJ Publishing
Refereed: Yes
Identification Number: https://doi.org/10.1136/jnnp-2018-320288
Related URLs:

Share / Export

Statistics